Biostandartas - Company finances
|
EUR
|
2021
From: 2021-09-21
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 2,400 | 14,000 | 243,320 | 297,150 | 655,970 |
| Profit before tax | - | - | - | - | 340,698 |
| Net profit | 1,948 | 6,108 | 23,319 | 27,630 | 340,698 |
| Equity | 4,948 | 131,055 | 154,375 | 182,005 | 522,703 |
| Liabilities | 520 | 123,897 | 1,064,486 | 902,995 | 753,697 |
| Non-current assets | 0 | 0 | 1,160,930 | 1,000,801 | 843,767 |
| Current assets | 5,468 | 254,952 | 57,931 | 83,476 | 432,345 |
| Total assets | 5,468 | 254,952 | 1,218,861 | 1,084,277 | 1,276,112 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 47,035 | 77,873 | 118,747 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +483.3% | +1638.0% | +22.1% | +120.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 35.6% | 2.4% | 1.9% | 2.5% | 26.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 39.4% | 4.7% | 15.1% | 15.2% | 65.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 81.2% | 43.6% | 9.6% | 9.3% | 51.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | 51.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.9 | 6.9 | 5.0 | 1.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 2,400 | 14,000 | 132,722 | 148,575 | 327,985 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biostandartas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-12-17 | 2024-12-17 | 917.25 |
| 2023-12-18 | 2024-01-02 | 0.10 |
| 2023-11-21 | 2023-12-03 | 0.10 |
| 2023-11-16 | 2023-11-20 | 24.37 |
| 2023-10-25 | 2023-11-05 | 0.10 |
| 2023-09-18 | 2023-09-20 | 92.14 |
| 2022-11-21 | 2022-12-04 | 0.04 |
| 2022-11-17 | 2022-11-18 | 0.04 |
| 2022-10-28 | 2022-11-07 | 0.04 |
| 2022-09-16 | 2022-09-25 | 4.79 |
| 2022-07-25 | 2022-07-28 | 4.84 |
| 2022-07-18 | 2022-07-24 | 4.81 |
| 2022-06-16 | 2022-07-17 | 0.02 |
| 2022-05-17 | 2022-06-05 | 0.02 |
| 2022-04-19 | 2022-05-08 | 4.81 |
| 2022-03-16 | 2022-04-18 | 0.02 |
| 2022-02-17 | 2022-03-03 | 0.02 |
| 2022-01-31 | 2022-02-03 | 0.02 |
| 2021-12-16 | 2021-12-28 | 4.73 |
| 2021-10-18 | 2021-10-20 | 1.19 |
Biostandartas - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-01-31 | 2025-02-20 | 1.29 |
| 2025-01-30 | 2025-01-30 | 1.56 |
| 2024-12-30 | 2025-01-15 | 1.56 |
| 2024-12-03 | 2024-12-12 | 1.56 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biostandartas, UAB (code 305903102) is a private limited liability company engaged in research and development in natural sciences. In the latest financial year, 2025, revenue increased to €656.0K from €297.1K in 2024 and €243.3K in 2023, confirming a strong upward trend over two years. Net profit rose to €340.7K in 2025, compared with €27.6K in 2024 and €23.3K in 2023, which lifted the profit margin to 51.9% from 9.3% and 9.6% in the previous years. At year-end 2025, total assets stood at €1.28M, equity at €522.7K and liabilities at €753.7K. Equity strengthened significantly versus 2024, while assets also expanded and liabilities remained substantial. Key efficiency indicators were solid: ROE was 65.2%, ROA 26.7% and asset turnover 0.51x. With revenue per employee of €328.0K and profit per employee of €170.3K, the company showed high productivity in 2025.